The serum estradiol/oocyte ratio in patients with breast cancer undergoing ovarian stimulation with letrozole and gonadotropins
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Objective To investigate the patterns of estradiol-oocyte ratio (EOR) and estradiol-mature oocyte ratio (EMOR) in patientswith breast cancer undergoing controlled ovarian stimulation (COS) using letrozole and gonadotropins for fertilitypreservation. Methods This retrospective study included 32 breast cancer patients underwent COS for fertility preservation and no patientshad previously undergone gonadotoxic treatments. Basal characteristics and in vitro fertilization (IVF) outcomes werecompared according to the age of women (age <35 vs. age ≥35) and the starting phase of ovarian stimulation (earlyfollicular phase vs. late follicular phase vs. luteal phase). Results Patients who were administered with a letrozole-combined regimen, the peak serum estradiol (E2) was maintainedat a low level (386.3±346.9 pg/mL). EOR was 52.4±78.8 pg/mL, and EMOR was 71.0±41.2 pg/mL. When the 2 groupswere compared according to the age of women (age <35 vs. age ≥35), EOR was 34.5 (22.2–46.5) pg/mL and 40.7(19.3–65.3) pg/mL, respectively; EMOR was 79.8 (40.8–90.6) pg/mL and 68.8 (44.5–85.9) pg/mL, respectively. There wasno significant difference in the IVF outcomes. When the 2 groups were compared according to the starting phase ofovarian stimulation, there were no significant differences in IVF outcomes, EOR and EMOR among the groups. Conclusion Measuring the peak E2 concentration in breast cancer patients undergoing IVF for fertility preservation with a cotreatmentof letrozole allows for the prediction of the numbers of oocytes and mature oocytes.
Abstract
Objective To investigate the patterns of estradiol-oocyte ratio (EOR) and estradiol-mature oocyte ratio (EMOR) in patientswith breast cancer undergoing controlled ovarian stimulation (COS) using letrozole and gonadotropins for fertilitypreservation. Methods This retrospective study included 32 breast cancer patients underwent COS for fertility preservation and no patientshad previously undergone gonadotoxic treatments. Basal characteristics and in vitro fertilization (IVF) outcomes werecompared according to the age of women (age <35 vs. age ≥35) and the starting phase of ovarian stimulation (earlyfollicular phase vs. late follicular phase vs. luteal phase). Results Patients who were administered with a letrozole-combined regimen, the peak serum estradiol (E2) was maintainedat a low level (386.3±346.9 pg/mL). EOR was 52.4±78.8 pg/mL, and EMOR was 71.0±41.2 pg/mL. When the 2 groupswere compared according to the age of women (age <35 vs. age ≥35), EOR was 34.5 (22.2–46.5) pg/mL and 40.7(19.3–65.3) pg/mL, respectively; EMOR was 79.8 (40.8–90.6) pg/mL and 68.8 (44.5–85.9) pg/mL, respectively. There wasno significant difference in the IVF outcomes. When the 2 groups were compared according to the starting phase ofovarian stimulation, there were no significant differences in IVF outcomes, EOR and EMOR among the groups. Conclusion Measuring the peak E2 concentration in breast cancer patients undergoing IVF for fertility preservation with a cotreatmentof letrozole allows for the prediction of the numbers of oocytes and mature oocytes.
참고문헌 (6)
- Orvieto R, "Controlled ovarian hyperstimulation: are we monitoring the appropriate sex-steroid hormones?", Fertil Steril, 89, pp.1269~1272 (2008)[DOI]
- Oktay K, "Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy", J Clin Endocrinol Metab, 91, pp.3885~3890 (2006)[DOI]
- Azim AA, "Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study", J Clin Oncol, 26, pp.2630~2635 (2008)[DOI]
- 김지현, "Efficacy of Random-start Controlled Ovarian Stimulation in Cancer Patients", Journal of Korean Medical Science, 30(3), pp.290~295 (2015), 대한의학회
- Loumaye E, "Assessment of the role of serum luteinizing hormone and estradiol response to follicle-stimulating hormone on in vitro fertilization treatment outcome", Fertil Steril, 67, pp.889~899 (1997)[DOI]
- Vaughan DA, "Serum estradiol:oocyte ratio as a predictor of reproductive outcome: an analysis of data from >9000 IVF cycles in the Republic of Ireland", J Assist Reprod Genet, 33, pp.481~488 (2016)[DOI]